Robert A Read more . Harrington, M.D., Gregg W. Stone, M.D., Steven McNulty, M.S., Harvey D. White, D.Sc., A. Michael Lincoff, M.D., C. Michael Gibson, M.D., Charles V. Pollack, Jr., M.D., Gilles Montalescot, M.D., Ph.D., Kenneth W. Mahaffey, M.D., Neal S. Kleiman, M.D., Shaun G. Goodman, M.D., Maged Amine, M.D., Dominick J. Angiolillo, M.D., Ph.D., Richard C. Becker, M.D., Derek P. Chew, M.B., B.S., M.P.H., William J. French, M.D., Franz Leisch, M.D., Keyur H. Parikh, M.D., Simona Skerjanec, Pharm.D., and Deepak L. Bhatt, M.D., M.P.H.: Platelet Inhibition with Cangrelor in Patients Undergoing PCI Percutaneous coronary intervention may be difficult by adverse cardiac events including death, myocardial infarction, a need for urgent revascularization, and severe, subacute, or late stent thrombosis, whether or not bare-metal or drug-eluting stents are used.
After screening, the level of HIV-1 RNA was measured at Johns Hopkins University. At the time of protocol-defined virologic failure, genotyping for drug level of resistance was performed at Stanford University; the baseline samples acquired from the sufferers were genotyped retrospectively. Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline provided the analysis medications and had input into the protocol advancement and overview of the manuscript. All the authors participated in the trial style, data analysis, and preparation of the manuscript, and all the authors attest to the accuracy and completeness of the reported data.